Corbus Pharma Q1 net loss $17M; pipeline on track for data in H2 2025

Corbus Pharmaceuticals Holdings, Inc.

2025-Q1 EPS reported -$1.39

Net loss of $17.0M ($1.39/share) vs $6.9M ($0.83) in Q1 2024; operating expenses rose to $19.8M.
Cash and investments $132.8M; expected to fund operations through Q2 2027.
CRB-701 Nectin-4 ADC dose optimization ongoing; RP2D expected Q4 2025; FDA Fast Track for cervical cancer.
CRB-913 CB1 inverse agonist Phase 1 SAD/MAD started March 2025; completion Q3 2025; Phase 1b starts Q4 2025.
CRB-601 anti-αvβ8 mAb Phase 1 dose escalation ongoing; completion expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.